173086-67-4

Upstream product

• 20555-91-3 3,4-dichloroiodobenzene 
• 98977-36-7 3-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3032-81-3 3,5-dichloroiodobenzene 
• 85275-45-2 N-tert-butoxycarbonyl-3-piperidinol 
• 6859-99-0 3-hydroxypiperazine 

Downstream Products

• 1010684-95-3 1,1-dimethylethyl 5-(3,4-dichlorophenyl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 749826-38-8 3-(3,4-dichloro-phenyl)-piperidin-3-ol 

Relevant academic research and scientific papers

CHEMICAL COMPOUNDS

The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof: formula (I), wherein G is selected from a group consisting of: phenyl, a 5- or 6-membered monocyclic heteroaryl group, or a

Thrombin receptor antagonists

A thrombin receptor antagonist having the formula or a pharmaceutically acceptable salt thereof, useful for inhibiting the aggregation of blood platelets. The compounds can be used in a method of acting upon a thrombin receptor which comprises administering a therapeutically effective but non-toxic amount of such compound to a mammal, preferably a human.

Discovery and initial structure-activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists

Thrombin is the most potent agonist of platelet activation, and its effects are predominantly mediated by platelet thrombin receptors. Therefore, antagonists of the thrombin receptor have potential utility for the treatment of thrombotic disorders. Screening of combinatorial libraries revealed 2 to be a potent antagonist of the thrombin receptor. Modifications of this structure produced 11k, which inhibits thrombin receptor stimulated secretion and aggregation of platelets.

SUBSTITUTED ARYLALIPHATIC COMPOUNDS, METHOD OF PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS IN WHICH THEY ARE PRESENT

Compound of Formula (I), wherein W 1 is an oxygen atom; an--NR--group wherein R is hydrogen, C 1-C 7 alkyl or benzyl; and B is for example a substituted piperidine or quinuclidine. The disclosed compounds are useful as neurokinin receptor antagonists.